HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: All these findings highlight the potential of synergistic combining HDAC inhibitors as a promising strategy for developing new therapies for CTCL, and the increased sensitivity to CPT following HDAC10 inhibition indicates that HDAC10 may play a protective role in Sézary cells.